Table 1 Demographic characteristics of men diagnosed with prostate cancer by use of different types of ADT
All patients | GnRH agonists plus antiandrogens | GnRH agonist only | Anti-androgen monotherapy | Orchiectomy only | Orchiectomy plus pharmacologic ADT | No ADT (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % | n | % | n | % | n | % | n | % | n | % | n | % | |
Age at diagnosis | ||||||||||||||
40–49 | 470 | 1.8 | 43 | 9.1 | 11 | 2.3 | 8 | 1.7 | 0 | 0.0 | 0 | 0.0 | 408 | 86.8 |
50–59 | 4388 | 17.2 | 454 | 10.3 | 216 | 4.9 | 120 | 2.7 | 9 | 0.2 | 30 | 0.7 | 3559 | 81.1 |
60–69 | 10,169 | 39.8 | 1440 | 14.2 | 905 | 8.9 | 397 | 3.9 | 33 | 0.3 | 107 | 1.1 | 7287 | 71.7 |
70–79 | 7363 | 28.8 | 1835 | 24.9 | 946 | 12.8 | 491 | 6.7 | 119 | 1.6 | 218 | 3.0 | 3754 | 51.0 |
80+ | 3154 | 12.3 | 1012 | 32.1 | 320 | 10.1 | 429 | 13.6 | 107 | 3.4 | 127 | 4.0 | 1159 | 36.7 |
Ethnicity | ||||||||||||||
European | 20,844 | 81.6 | 3870 | 18.6 | 1923 | 9.2 | 1184 | 5.7 | 233 | 1.1 | 413 | 2.0 | 13,221 | 63.4 |
Maori | 1345 | 5.3 | 353 | 26.2 | 136 | 10.1 | 73 | 5.4 | 23 | 1.7 | 40 | 3.0 | 720 | 53.5 |
Pacific_Island | 649 | 2.5 | 165 | 25.4 | 59 | 9.1 | 63 | 9.7 | 7 | 1.1 | 16 | 2.5 | 339 | 52.2 |
Asian | 468 | 1.8 | 88 | 18.8 | 58 | 12.4 | 35 | 7.5 | 3 | 0.6 | 4 | 0.9 | 280 | 59.8 |
Other | 95 | 0.4 | 17 | 17.9 | 10 | 10.5 | 7 | 7.4 | 1 | 1.1 | 0 | 0.0 | 60 | 63.2 |
Non-specify | 2143 | 8.4 | 291 | 13.6 | 212 | 9.9 | 83 | 3.9 | 1 | 0.0 | 9 | 0.4 | 1547 | 72.2 |
Year of PCa diagnosis | ||||||||||||||
2004 | 2715 | 10.6 | 483 | 17.8 | 203 | 7.5 | 271 | 10.0 | 59 | 2.2 | 107 | 3.9 | 1592 | 58.6 |
2005 | 2503 | 9.8 | 466 | 18.6 | 196 | 7.8 | 239 | 9.5 | 51 | 2.0 | 73 | 2.9 | 1478 | 59.0 |
2006 | 2446 | 9.6 | 505 | 20.6 | 224 | 9.2 | 181 | 7.4 | 41 | 1.7 | 79 | 3.2 | 1416 | 57.9 |
2007 | 2892 | 11.3 | 570 | 19.7 | 301 | 10.4 | 170 | 5.9 | 39 | 1.3 | 66 | 2.3 | 1746 | 60.4 |
2008 | 2896 | 11.3 | 606 | 20.9 | 335 | 11.6 | 146 | 5.0 | 23 | 0.8 | 55 | 1.9 | 1731 | 59.8 |
2009 | 3298 | 12.9 | 655 | 19.9 | 328 | 9.9 | 130 | 3.9 | 23 | 0.7 | 52 | 1.6 | 2110 | 64.0 |
2010 | 2890 | 11.3 | 558 | 19.3 | 268 | 9.3 | 123 | 4.3 | 18 | 0.6 | 33 | 1.1 | 1890 | 65.4 |
2011 | 2918 | 11.4 | 514 | 17.6 | 307 | 10.5 | 87 | 3.0 | 8 | 0.3 | 11 | 0.4 | 1991 | 68.2 |
2012 | 2986 | 11.7 | 427 | 14.3 | 236 | 7.9 | 98 | 3.3 | 6 | 0.2 | 6 | 0.2 | 2213 | 74.1 |
Extent of disease at diagnosis | ||||||||||||||
Localised | 3810 | 14.9 | 51 | 1.3 | 32 | 0.8 | 63 | 1.7 | 16 | 0.4 | 10 | 0.3 | 3638 | 95.5 |
Regional spread | 1770 | 6.9 | 314 | 17.7 | 163 | 9.2 | 69 | 3.9 | 8 | 0.5 | 26 | 1.5 | 1190 | 67.2 |
Metastatic | 1341 | 5.2 | 673 | 50.2 | 77 | 5.7 | 227 | 16.9 | 38 | 2.8 | 112 | 8.4 | 214 | 16.0 |
Unknown | 18,623 | 72.9 | 3746 | 20.1 | 2126 | 11.4 | 1086 | 5.8 | 206 | 1.1 | 334 | 1.8 | 11,125 | 59.7 |
Bisphosphonates | ||||||||||||||
Yes | 1301 | 5.1 | 398 | 30.6 | 166 | 12.8 | 96 | 7.4 | 39 | 3.0 | 47 | 3.6 | 555 | 42.7 |
No | 24,243 | 94.9 | 4386 | 18.1 | 2232 | 9.2 | 1349 | 5.6 | 229 | 0.9 | 435 | 1.8 | 15,612 | 64.4 |